News
10 June 2021
Dear world: meet ELOF1 – the newly discovered core factor in the TC-NER pathway
Damaged DNA is a problem for cells. DNA replication and transcription are hampered if the DNA template is damaged. Moreover, accumulating DNA damage is one of the hallmarks of cancer. Luckily our cells are equipped with machineries to fix damaged DNA. Until now, we only knew three core factors that could recognize DNA damage-stalled RNA polymerase: CSA, CSB and UVSSA. Using CRISPR/Cas9 technology Oncode Investigator Jurgen Marteijn’s new research has identified a fourth core factor, called ELOF1. The results of this research are now published in Nature Cell Biology.
News
8 June 2021
Oncode Investigators Karin de Visser and Wim Vermeulen elected to the prestigious EMBO membership
Oncode Investigators Karin de Visser (NKI) and Wim Vermeulen (ErasmusMC) are part of the 64 newly elected life scientists to the prestigious EMBO membership this year. The membership recognizes outstanding achievements in the life sciences and members are actively involved in the EMBO organization and beyond.
News
7 June 2021
The development of novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors
Researchers from the group of Oncode Investigator Wouter de Laat (Hubrecht Institute), in collaboration with biotech company Cergentis and lymphoma experts of 5 Dutch hospitals, developed a novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors. The method, FFPE-TLC technology, promises to improve diagnostics for lymphoma and may also be relevant for rearrangement detection in other cancers such as sarcoma and lung- and prostate cancer.
News
4 June 2021
2020: Accelerating to Full Speed
The year 2020 was extraordinary for everyone. Although COVID-19 also affected Oncode, we are proud to share the successes we achieved in 2020. By further building on our three pillars - scientific excellence, collaboration, and valorization - all the hard work of our community in the last years starts to bear fruits.
Vesnade Jong
<span>Vesna</span><span>de Jong</span>
Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
News
2 June 2021
Researchers find new method to reduce the risk of developing colon cancer
The team of Oncode Investigator Louis Vermeulen (Amsterdam UMC, location AMC) has used organoid technology and the application of lithium to discover how the chance of polyps forming in the intestine, and thus the development of colorectal cancer, can be reduced. Competition between stem cells in the gut plays a key role in this. The results appeared in the leading journal Nature today.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Meet Oncode
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more